Commission Delegated Regulation (EU) 2021/849 of 11 March 2021 amending, for the purposes of its adaptation to technical and scientific progress, Part 3 of Annex VI to Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)

ANNEX
ANNEX
In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:
(1)
the following entries are inserted:
Index No
Chemical Name
EC No
CAS No
Classification
Labelling
Specific Conc. Limits, M-
factors and ATE
Notes
Hazard Class and Category Code(s)
Hazard statement Code(s)
Pictogram, Signal Word Code(s)
Hazard statement Code(s)
Suppl. Hazard statement Code(s)
‘601-093-00-6
1,4-dimethylnaphthalene
209-335-9
571-58-4
Acute Tox. 4
Asp. Tox. 1
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 3
H302
H304
H319
H400
H412
GHS07
GHS08
GHS09
Dgr
H302
H304
H319
H410
oral: ATE = 1 300 mg/kg bw
M = 1’
‘601-094-00-1
1-isopropyl-4-methylbenzene;
p -cymene
202-796-7
99-87-6
Flam. Liq. 3
Acute Tox. 3
Asp. Tox. 1
Aquatic Chronic 2
H226
H331
H304
H411
GHS02
GHS06
GHS08
GHS09
Dgr
H226
H331
H304
H411
inhalation: ATE = 3 mg/l (vapours)’
‘601-095-00-7
p -mentha-1,3-diene; 1-isopropyl-4-methylcyclohexa-1,3-diene;
alpha-terpinene
202-795-1
99-86-5
Flam. Liq. 3
Acute Tox. 4
Skin Sens. 1
Asp. Tox. 1
Aquatic Chronic 2
H226
H302
H317
H304
H411
GHS02
GHS07
GHS08
GHS09
Dgr
H226
H302
H317
H304
H411
oral: ATE = 1 680 mg/kg bw’
‘602-110-00-X
tetrafluoroethylene
204-126-9
116-14-3
Carc. 1B
H350
GHS08
Dgr
H350’
‘604-095-00-5
6,6'-di- tert -butyl-2,2'-methylenedi- p -cresol;
[DBMC]
204-327-1
119-47-1
Repr. 1B
H360F
GHS08
Dgr
H360F’
‘606-152-00-X
(5-chloro-2-methoxy-4-methyl-3-pyridyl)(4,5,6-trimethoxy- o -tolyl)methanone; pyriofenone
-
688046-61-9
Carc. 2
Aquatic Chronic 1
H351
H410
GHS08
GHS09
Wng
H351
H410
M = 1’
‘607-747-00-7
2,2-dibromo-2-cyanoacetamide; [DBNPA]
233-539-7
10222-01-2
Acute Tox. 2
Acute Tox. 3
STOT RE 1
Skin Irrit. 2
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H330
H301
H372 (respiratory tract) (inhalation)
H315
H318
H317
H400
H410
GHS06
GHS08
GHS05
GHS09
Dgr
H330
H301
H372 (respiratory tract) (inhalation)
H315
H318
H317
H410
inhalation: ATE = 0,24 mg/l (dusts or mists)
oral: ATE = 118 mg/kg bw
M = 1
M = 1’
‘607-748-00-2
[ S -( Z , E )]-5-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)-3-methylpenta-2,4-dienoic acid;
S -abscisic acid
244-319-5
21293-29-8
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410
M = 1
M = 1’
‘607-749-00-8
methyl salicylate
204-317-7
119-36-8
Repr. 2
Acute Tox. 4
Skin Sens. 1B
Aquatic Chronic 3
H361d
H302
H317
H412
GHS07
GHS08
Wng
H361d
H302
H317
H412
oral: ATE = 890 mg/kg bw’
‘607-750-00-3
citric acid
201-069-1
77-92-9
Eye Irrit. 2
STOT SE 3
H319
H335
GHS07
Wng
H319
H335’
‘607-751-00-9
ethametsulfuron-methyl (ISO);
methyl 2-({[4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)benzoate
-
97780-06-8
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H319
H400
H410
GHS07
GHS09
Wng
H319
H410
M = 1 000
M = 100’
‘607-752-00-4
trinexapac-ethyl (ISO);
ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate
-
95266-40-3
STOT RE 2
Skin Sens. 1B
Aquatic Chronic 1
H373 (gastrointestinal tract)
H317
H410
GHS08
GHS07
GHS09
Wng
H373 (gastrointestinal tract)
H317
H410
M = 1’
‘607-753-00-X
(3a S ,5 S ,6 R ,7a R ,7b S ,9a S ,10 R ,12a S ,12b S )-10-[(2 S ,3 R ,4 R ,5 R )-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3 H -benzo[ c ]indeno[5,4- e ]oxepin-3-one; 24-epibrassinolide
-
78821-43-9
Aquatic Chronic 4
H413
H413’
‘607-754-00-5
benzyl salicylate
204-262-9
118-58-1
Skin Sens. 1B
H317
GHS07
Wng
H317’
‘607-755-00-0
( RS )-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)- o -toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate;
tolpyralate
-
1101132-67-5
Carc. 2
Repr. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H361fd
H373 (eye)
H400
H410
GHS08
GHS09
Wng
H351
H361fd
H373 (eye)
H410
M = 10
M = 100’
‘613-337-00-9
prothioconazole (ISO);
2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-3 H -1,2,4-triazole-3-thione
-
178928-70-6
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410
M = 10
M = 1’
‘613-338-00-4
azamethiphos (ISO); S -[(6-chloro-2-oxooxazolo[4,5- b ]pyridin-3(2 H )-yl)methyl] O , O -dimethyl thiophosphate
252-626-0
35575-96-3
Carc. 2
Acute Tox. 3
Acute Tox. 4
STOT SE 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H331
H302
H370 (nervous system)
H317
H400
H410
GHS06
GHS08
GHS09
Dgr
H351
H331
H302
H370 (nervous system)
H317
H410
inhalation: ATE = 0,5 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 1 000
M = 1 000 ’
‘613-339-00-X
3-methylpyrazole
215-925-7
1453-58-3
Repr. 1B
Acute Tox. 4
STOT RE 2
Skin Corr. 1
Eye Dam. 1
H360D
H302
H373 (lung)
H314
H318
GHS08
GHS07
GHS05
Dgr
H360D
H302
H373 (lung)
H314
oral: ATE = 500 mg/kg bw’
‘613-340-00-5
clomazone (ISO); 2-(2-chlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one
-
81777-89-1
Acute Tox. 4
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H332
H302
H400
H410
GHS07
GHS09
Wng
H332
H302
H410
inhalation: ATE = 4,85 mg/l (dusts or mists)
oral: ATE = 768 mg/kg bw
M = 1
M = 1’
‘614-030-00-2
emamectin benzoate (ISO); (4" R )-4"-deoxy-4"-(methylamino) avermectin B1 benzoate
-
155569-91-8
Acute Tox. 3
Acute Tox. 3
Acute Tox. 3
STOT SE 1
STOT RE 1
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H331
H311
H301
H370 (nervous system)
H372 (nervous system)
H318
H400
H410
GHS06
GHS05
GHS08
GHS09
Dgr
H331
H311
H301
H370 (nervous system)
H372 (nervous system)
H318
H410
inhalation:
ATE = 0,663
mg/l (dusts or mists)
dermal:
ATE = 300
mg/kg bw
oral: ATE =
60 mg/kg bw
STOT RE 1; H372: C ≥ 5 %; STOT RE 2; H373: 0,5 % ≤ C < 5 %
M = 10 000
M = 10 000 ’
‘616-234-00-7
N -methoxy- N -[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen
-
1228284-64-7
Carc. 2
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1
H351
H361f
H400
H410
GHS08
GHS09
Wng
H351
H361f
H410
M = 1
M = 1’
‘616-235-00-2
N -{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1 H -pyrazole-4-carboxamide; sedaxane
-
874967-67-6
Carc. 2
Aquatic Acute 1
Aquatic Chronic 2
H351
H400
H411
GHS08
GHS09
Wng
H351
H410
M = 1’
(2)
the entries corresponding to index numbers 005-007-00-2; 005-008-00-8; 005-011-00-4; 005-011-01-1; 005-011-02-9; 006-069-00-3; 006-076-00-1; 015-113-00-0; 028-007-00-4; 029-002-00-X; 029-015-00-0; 029-016-00-6; 029-017-00-1; 029-018-00-7; 029-019-01-X; 029-020-00-8; 029-021-00-3; 029-022-00-9; 029-023-00-4; 601-029-00-7; 601-096-00-2; 603-024-00-5; 603-066-00-4; 603-098-00-9; 606-004-00-4; 607-421-00-4; 607-424-00-0; 607-434-00-5; 608-058-00-4; 612-067-00-9; 612-252-00-4; 613-048-00-8; 613-102-00-0; 613-111-00-X; 613-166-00-X; 613-208-00-7; 613-267-00-9; 613-282-00-0; 616-032-00-9; 616-106-00-0 and 616-113-00-9 are replaced by the following entries respectively:
Index No
Chemical Name
EC No
CAS No
Classification
Labelling
Specific Conc. Limits, M- factors and ATE
Notes
Hazard Class and Category Code(s)
Hazard statement Code(s)
Pictogram, Signal Word Code(s)
Hazard statement Code(s)
Suppl. Hazard statement Code(s)
‘005-007-00-2
boric acid [1]
boric acid [2]
233-139-2 [1]
234-343-4 [2]
10043-35-3 [1]
11113-50-1 [2]
Repr. 1B
H360FD
GHS08
Dgr
H360FD’
‘005-008-00-8
diboron trioxide
215-125-8
1303-86-2
Repr. 1B
H360FD
GHS08
Dgr
H360FD’
‘005-011-00-4
tetraboron disodium heptaoxide, hydrate; [1]
disodium tetraborate, anhydrous; [2]
orthoboric acid, sodium salt [3]
disodium tetraborate decahydrate [4]
disodium tetraborate pentahydrate [5]
235-541-3 [1]
215-540-4 [2]
237-560-2 [3]
215-540-4 [4]
215-540-4 [5]
12267-73-1 [1]
1330-43-4 [2]
13840-56-7 [3]
1303-96-4 [4]
12179-04-3 [5]
Repr. 1B
H360FD
GHS08
Dgr
H360FD’
‘006-069-00-3
thiophanate-methyl (ISO);
dimethyl (1,2-phenylenedicarbamothioyl)biscarbamate;
dimethyl 4,4′-( o -phenylene)bis(3-thioallophanate)
245-740-7
23564-05-8
Carc. 2
Muta. 2
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H341
H332
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H351
H341
H332
H317
H410
inhalation: ATE = 1,7 mg/l
(dusts and mists)
M = 10
M = 10’
‘006-076-00-1
mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt
-
8018-01-7
Carc. 2
Repr. 1B
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H351
H360D
H373 (thyroid, nervous system)
H317
H400
H410
GHS08
GHS07
GHS09
Dgr
H351
H360D
H373 (thyroid, nervous system)
H317
H410
M = 10
M = 10’
‘015-113-00-0
tolclofos-methyl (ISO);
O -(2,6-dichloro- p -tolyl) O , O -dimethyl thiophosphate
260-515-3
57018-04-9
Skin Sens. 1B
Aquatic Acute 1
Aquatic Chronic 1
H317
H400
H410
GHS07
GHS09
Wng
H317
H410
M = 1
M = 1’
‘028-007-00-4
trinickel disulfide;
nickel subsulfide; [1]
heazlewoodite [2]
234-829-6 [1]
- [2]
12035-72-2 [1]
12035-71-1 [2]
Carc. 1A
Muta. 2
Acute Tox. 3
STOT RE 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H350i
H341
H331
H372**
H317
H400
H410
GHS08
GHS06
GHS09
Dgr
H350i
H341
H331
H372**
H317
H410
inhalation:
ATE = 0,92 mg/l
(dusts or mists)’
‘029-002-00-X
dicopper oxide;
copper (I) oxide
215-270-7
1317-39-1
Acute Tox. 4
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H332
H302
H318
H400
H410
GHS07
GHS05
GHS09
Dgr
H332
H302
H318
H410
inhalation: ATE = 3,34 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 100
M = 10’
‘029-015-00-0
copper thiocyanate
214-183-1
1111-67-7
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410
EUH032
M = 10
M = 10’
‘029-016-00-6
copper(II) oxide
215-269-1
1317-38-0
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410
M = 100
M = 10’
‘029-017-00-1
dicopper chloride trihydroxide
215-572-9
1332-65-6
Acute Tox. 4
Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1
H332
H301
H400
H410
GHS06
GHS09
Dgr
H332
H301
H410
inhalation: ATE = 2,83 mg/l (dusts or mists)
oral: ATE = 299 mg/kg bw
M = 10
M = 10’
‘029-018-00-7
tetracopper hexahydroxide sulphate; [1]
tetracopper hexahydroxide sulphate hydrate [2]
215-582-3 [1]
215-582-3 [2]
1333-22-8 [1]
12527-76-3 [2]
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H302
H400
H410
GHS07
GHS09
Wng
H302
H410
oral: ATE = 500 mg/kg bw
M = 10
M = 10’
‘029-019-01-X
copper flakes (coated with aliphatic acid)
-
-
Acute Tox. 3
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H331
H302
H319
H400
H410
GHS06
GHS09
Dgr
H331
H302
H319
H410
inhalation: ATE = 0,733 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 10
M = 10’
‘029-020-00-8
copper(II) carbonate—copper(II) hydroxide (1:1)
235-113-6
12069-69-1
Acute Tox. 4
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H332
H302
H319
H400
H410
GHS07
GHS09
Wng
H332
H302
H319
H410
inhalation: ATE = 1,2 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 10
M = 10’
‘029-021-00-3
copper dihydroxide;
copper(II) hydroxide
243-815-9
20427-59-2
Acute Tox. 2
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H330
H302
H318
H400
H410
GHS06
GHS05
GHS09
Dgr
H330
H302
H318
H410
inhalation: ATE = 0,47 mg/l (dusts or mists)
oral: ATE = 500 mg/kg bw
M = 10
M = 10’
‘029-022-00-9
bordeaux mixture;
reaction products of copper sulphate with calcium dihydroxide
-
8011-63-0
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H332
H318
H400
H410
GHS07
GHS05
GHS09
Dgr
H332
H318
H410
inhalation: ATE = 1,97 mg/l (dusts or mists)
M = 10
M = 1’
‘029-023-00-4
copper sulphate pentahydrate
231-847-6
7758-99-8
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H302
H318
H400
H410
GHS07
GHS05
GHS09
Dgr
H302
H318
H410
oral: ATE = 481 mg/kg bw
M = 10
M = 1’
‘601-029-00-7
dipentene;
limonene [1]
( S )- p -mentha-1,8-diene; l-limonene [2]
trans -1-methyl-4-(1-methylvinyl)cyclohexene; [3]
(±)-1-methyl-4-(1-methylvinyl)cyclohexene [4]
205-341-0 [1]
227-815-6 [2]
229-977-3 [3]
231-732-0 [4]
138-86-3 [1]
5989-54-8 [2]
6876-12-6 [3]
7705-14-8 [4]
Flam. Liq. 3
Skin Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H226
H315
H317
H400
H410
GHS02
GHS07
GHS09
Wng
H226
H315
H317
H410
C’
‘601-096-00-2
( R )- p -mentha-1,8-diene;
d-limonene
227-813-5
5989-27-5
Flam. Liq. 3
Skin Irrit. 2
Skin Sens. 1B
Asp. Tox. 1
Aquatic Acute 1
Aquatic Chronic 3
H226
H315
H317
H304
H400
H412
GHS02
GHS07
GHS08
GHS09
Dgr
H226
H315
H317
H304
H410
M = 1’
‘603-024-00-5
1,4-dioxane
204-661-8
123-91-1
Flam. Liq. 2
Carc. 1B
STOT SE 3
Eye Irrit. 2
H225
H350
H335
H319
GHS02
GHS08
GHS07
Dgr
H225
H350
H335
H319
EUH019
EUH066
D’
‘603-066-00-4
7-oxa-3-oxiranylbicyclo[4.1.0]heptane; 1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide
203-437-7
106-87-6
Carc. 1B
Muta. 2
Repr. 1B
Acute Tox. 3
Acute Tox. 4
H350
H341
H360F
H331
H302
GHS08
GHS06
Dgr
H350
H341
H360F
H331
H302
inhalation: ATE = 0,5 mg/l (dusts or mists)
oral: ATE = 1 847 mg/kg bw’
‘603-098-00-9
2-phenoxyethanol
204-589-7
122-99-6
Acute Tox. 4
STOT SE 3
Eye Dam. 1
H302
H335
H318
GHS05
GHS07
Dgr
H302
H335
H318
oral:
ATE = 1 394 mg/kg bw’
‘606-004-00-4
4-methylpentan-2-one; isobutyl methyl ketone
203-550-1
108-10-1
Flam. Liq. 2
Carc. 2
Acute Tox. 4
STOT SE 3
Eye Irrit. 2
H225
H351
H332
H336
H319
GHS02
GHS07
GHS08
Dgr
H225
H351
H332
H336
H319
EUH066
inhalation: ATE = 11 mg/l (vapours)’
‘607-421-00-4
cypermethrin (ISO);
α-cyano-3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; cypermethrin cis/trans +/- 40/60
257-842-9
52315-07-8
Acute Tox. 4
Acute Tox. 4
STOT SE 3
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H332
H302
H335
H373 (nervous system)
H400
H410
GHS07
GHS08
GHS09
Wng
H332
H302
H335
H373 (nervous system)
H410
oral; ATE = 500 mg/kg bw
inhalation; ATE = 3,3 mg/l (dusts or mists)
M = 100000
M = 100000’
‘607-424-00-0
trifloxystrobin (ISO); methyl ( E )-methoxyimino-{( E )-α-[1-(α,α,α-trifluoro- m -tolyl)ethylideneaminooxy]- o -tolyl}acetate
-
141517-21-7
Lact.
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H362
H317
H400
H410
GHS07
GHS09
Wng
H362
H317
H410
M = 100
M = 10’
‘607-434-00-5
mecoprop-P (ISO) [1] and its salts;
( R )-2-(4-chloro-2-methylphenoxy)propionic acid [1] and its salts
240-539-0 [1]
16484-77-8 [1]
Acute Tox. 4
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H302
H318
H400
H410
GHS07
GHS05
GHS09
Dgr
H302
H318
H410
oral: ATE = 431 mg/kg bw
M = 10
M = 10’
‘608-058-00-4
esfenvalerate (ISO);
(S)-α-cyano-3-phenoxybenzyl-( S )-2-(4-chlorophenyl)-3-methylbutyrate
-
66230-04-4
Acute Tox. 3
Acute Tox. 3
STOT SE 1
STOT RE 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H331
H301
H370 (nervous system)
H373
H317
H400
H410
GHS06
GHS08
GHS09
Dgr
H331
H301
H370 (nervous system)
H373
H317
H410
oral; ATE = 88,5 mg/kg bw
inhalation; ATE = 0,53 mg/l (dusts or mists)
M = 10 000
M = 10 000 ’
‘612-067-00-9
3-aminomethyl-3,5,5-trimethylcyclohexylamine
220-666-8
2855-13-2
Acute Tox. 4
Skin Corr. 1B
Eye Dam. 1
Skin Sens. 1A
H302
H314
H318
H317
GHS05
GHS07
Dgr
H302
H314
H317
oral: ATE = 1 030 mg/kg bw
Skin Sens. 1A; H317: C ≥ 0,001 %’
‘612-252-00-4
imidacloprid (ISO);
( E )-1-(6-chloro-3-pyridylmethyl)- N -nitroimidazolidin-2-ylideneamine;
(2 E )-1-[(6-chloropyridin-3-yl) methyl]- N -nitroimidazolidin-2-imine
428-040-8
138261-41-3
Acute Tox. 3
Aquatic Acute 1
Aquatic Chronic 1
H301
H400
H410
GHS06
GHS09
Dgr
H301
H410
oral: ATE = 131 mg/kg bw
M = 100
M = 1 000 ’
‘613-048-00-8
carbendazim (ISO); methyl benzimidazol-2-ylcarbamate
234-232-0
10605-21-7
Muta. 1B
Repr. 1B
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H340
H360FD
H317
H400
H410
GHS07
GHS08
GHS09
Dgr
H340
H360FD
H317
H410
M = 10
M = 10’
‘613-102-00-0
dimethomorph (ISO); ( E , Z )-4-(3-(4-chlorophenyl)-3-(3,4-dimethoxyphenyl)acryloyl)morpholine
404-200-2
110488-70-5
Repr. 1B
Aquatic Chronic 2
H360F
H411
GHS08
GHS09
Dgr
H360F
H411’
‘613-111-00-X
1,2,4-triazole
206-022-9
288-88-0
Repr. 1B
Acute Tox. 4
Eye Irrit. 2
H360FD
H302
H319
GHS08
GHS07
Dgr
H360FD
H302
H319
oral: ATE = 1 320 mg/kg bw’
‘613-166-00-X
flumioxazin (ISO);
N -(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2 H -1,4-benzoxazin-6-yl)cyclohex-1-ene-1,2-dicarboximide
-
103361-09-7
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1
H361d
H400
H410
GHS08
GHS09
Wng
H361d
H410
M = 1 000
M = 1 000 ’
‘613-208-00-7
imazamox (ISO);
( RS )-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid
-
114311-32-9
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1
H361d
H400
H410
GHS08
GHS09
Wng
H361d
H410
M = 10
M = 10’
‘613-267-00-9
thiamethoxam (ISO);
3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene- N -nitroamine
428-650-4
153719-23-4
Repr. 2
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1
H361fd
H302
H400
H410
GHS07
GHS08
GHS09
Wng
H361fd
H302
H410
oral: ATE = 780 mg/kg bw
M = 10
M = 10’
‘613-282-00-0
triticonazole (ISO);
( RS )-( E )-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1 H -1,2,4-triazol-1-methyl)cyclopentanol
-
138182-18-0
Repr. 2
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
H361f
H373
H400
H410
GHS08
GHS09
Wng
H361f
H373
H410
M = 1
M = 1’
‘616-032-00-9
diflufenican (ISO);
N -(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide; 2′,4′-difluoro-2-(α,α,α-trifluoro- m -tolyloxy) nicotinanilide
-
83164-33-4
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410
M = 10 000
M = 1 000 ’
‘616-106-00-0
phenmedipham (ISO); methyl 3-(3-methylcarbaniloyloxy)carbanilate
237-199-0
13684-63-4
Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410
M = 10
M = 10’
‘616-113-00-9
desmedipham (ISO);
ethyl 3-phenylcarbamoyloxyphenylcarbamate
237-198-5
13684-56-5
Repr. 2
Aquatic Acute 1
Aquatic Chronic 1
H361d
H400
H410
GHS08
GHS09
Wng
H361d
H410
M = 10
M = 10’
(3)
the entry corresponding to index number 015-192-00-1 is deleted.
Schedules & Appendices

Cite this act
